Estrogen Therapy for Menopause: What Doctors Prescribe (2026)

Estrogen therapy for menopause covers a wide range of formulations, doses, and delivery routes — and what a clinician actually prescribes depends on your symptom burden, lab results, uterine status, and cardiovascular history, not a one-size protocol. This guide walks through the clinical decision tree the way a licensed clinician uses it in 2026.

TL;DR: Estrogen therapy for menopause is the most effective treatment for vasomotor symptoms (hot flashes, night sweats) and genitourinary atrophy. In 2026, most clinicians prescribe transdermal estradiol over oral conjugated estrogens because it avoids first-pass liver metabolism and carries a lower clot risk. Progestogen is added for anyone with an intact uterus. Dose is titrated against symptoms and serum estradiol levels, typically targeting 50–100 pg/mL. GoodLife Health clinicians build individualized protocols after reviewing labs — not before.

Why this matters

The Women's Health Initiative study in 2002 triggered a 50% drop in hormone prescribing that took over a decade to partially reverse. Subsequent re-analyses showed the risk signals applied specifically to oral conjugated equine estrogen plus medroxyprogesterone acetate in older postmenopausal women — not to transdermal estradiol or bioidentical progesterone in recently menopausal women. The 2022 Menopause Society position statement and the 2023 NICE guideline both affirm that for healthy women under 60 or within 10 years of menopause onset, the benefit-risk balance of systemic estrogen therapy is favorable. That context shapes every prescription decision below.

What you'll need before starting

• A baseline hormone panel: serum estradiol (E2), FSH, LH, and SHBG
• Metabolic markers: fasting glucose, lipid panel, liver enzymes (especially if oral route is being considered)
• Uterine status confirmed: hysterectomy or intact uterus — this determines whether progestogen is required
• Blood pressure reading: hypertension is a relative contraindication for oral estrogen
• Personal and family history: clotting disorders, hormone-sensitive cancers, cardiovascular disease
• Symptom severity score: the Menopause Rating Scale (MRS) or Greene Climacteric Scale gives the clinician a baseline to measure against at 8–12 weeks
• Time: plan for a 45–60 minute intake visit, plus 2–3 weeks for labs to return before a prescription is written

GoodLife Health clinicians at hormone optimization order and interpret all baseline labs as part of the membership — you do not arrange labs separately.

The steps: how a clinician builds your estrogen protocol

Step 1 — Confirm the diagnosis and rule out contraindications

Menopause is defined as 12 consecutive months without a menstrual period. Perimenopause, which can last 4–10 years, often produces the worst symptoms while FSH and estradiol are still fluctuating. A single lab draw can mislead; your clinician looks at FSH above 30–40 mIU/mL combined with low E2 and clinical symptoms together.

Absolute contraindications include: active or recent hormone-sensitive breast or endometrial cancer, unexplained vaginal bleeding, active deep vein thrombosis or pulmonary embolism, active liver disease, and known thrombophilia (e.g. Factor V Leiden). If any apply, systemic estrogen is off the table and the visit pivots to non-hormonal options.

Common mistake: Assuming a BRCA1/2 carrier status is an absolute contraindication. It is not, for women who have undergone risk-reducing surgery. That decision requires oncology co-management, but it is not automatic disqualification.

Step 2 — Choose the delivery route: transdermal first, oral second

Route selection is the most consequential decision in the protocol. Transdermal estradiol (patches, gels, sprays) delivers estradiol directly into circulation, bypassing the liver. Oral estrogen undergoes hepatic first-pass metabolism, which raises CRP, SHBG, and triglycerides, and increases clot risk by roughly 2-fold compared to transdermal in observational data through 2026.

Transdermal estradiol: 0.025 mg/day patch (low starting dose) up to 0.1 mg/day. Gel (0.75 mg/actuation) and spray formulations offer easier titration. Gels are applied daily to the inner arm or thigh.

Oral estradiol: 0.5–2 mg/day. Reserved for patients who cannot tolerate topical preparations or who have specific clinical reasons. Not conjugated equine estrogens (Premarin) — oral estradiol is bioidentical and has a cleaner risk profile than CEE, though still less favorable than transdermal.

Vaginal estrogen (local, low-dose): Estradiol cream, ring (Estring, 7.5 mcg/day), or tablet (Vagifem 10 mcg) for genitourinary syndrome of menopause (GSM) — dryness, pain with intercourse, recurrent UTIs. Local vaginal estrogen produces negligible systemic absorption at labeled doses and does not require progestogen even in women with an intact uterus.

Expected outcome: Most patients using transdermal estradiol at 0.05 mg/day see 60–80% reduction in hot flash frequency within 4–6 weeks.

Common mistake: Starting at the highest dose to get faster relief. Higher starting doses increase breakthrough bleeding and make dose adjustments harder to interpret.

Step 3 — Add progestogen if the uterus is intact

Estrogen alone in a woman with an intact uterus stimulates endometrial proliferation and raises endometrial cancer risk. Progestogen counteracts this. The two main options:

Micronized progesterone (Prometrium / generic): Bioidentical. 100 mg/day continuous or 200 mg/day for 12 days per month (sequential). Better sleep-side-effect profile than synthetic progestins. Preferred by most evidence-based clinicians in 2026.

Synthetic progestins (medroxyprogesterone acetate, norethindrone): Still used; MPA was the progestogen in the original WHI. Some data suggest less favorable breast and cardiovascular profiles compared to micronized progesterone. Used when cost or formulation access is a factor.

Women who have had a hysterectomy take estrogen alone — adding progestogen provides no benefit and adds unnecessary exposure.

Expected outcome: Endometrial protection confirmed at 12 months via transvaginal ultrasound if breakthrough bleeding occurs; endometrial stripe under 4 mm is the target.

Step 4 — Set the starting dose and titration schedule

A starting transdermal patch dose of 0.05 mg/day is appropriate for most women with moderate-to-severe vasomotor symptoms. A follow-up serum E2 level at 6–8 weeks guides titration: target is 50–100 pg/mL in most symptomatic women, though some need 100–150 pg/mL for adequate symptom control.

Titration ladder:

• 0.025 mg/day → for mild symptoms or older patients (over 65) being started cautiously
• 0.05 mg/day → standard starting dose for moderate symptoms
• 0.075 mg/day → if symptoms persist and E2 is below 50 pg/mL at 8 weeks
• 0.1 mg/day → upper end; rarely needed; re-evaluate root cause if symptoms persist here

Do not titrate based on symptoms alone. A serum E2 at 8 weeks prevents overshooting.

Common mistake: Stopping therapy at 12 months because of a vague "rule" that estrogen should not be used long-term. No major guideline in 2026 sets a blanket time limit. Duration is individualized based on ongoing risk-benefit assessment.

Step 5 — Monitor at 8–12 weeks, then annually

At 8–12 weeks:

• Repeat serum E2 and symptom score (MRS)
• Blood pressure check
• Ask about breast tenderness, irregular bleeding, mood changes
• Adjust dose or formulation if needed

Annually:

• Full hormone panel (E2, FSH, SHBG, progesterone if on progestogen)
• Metabolic panel
• Mammogram (per standard screening intervals — estrogen therapy does not require additional mammography frequency in most guidelines)
• Blood pressure
• Symptom reassessment
• Shared decision-making on continuation

At GoodLife Health, clinicians review your annual labs and update your protocol within the membership — no separate "follow-up visit fee."

Troubleshooting common problems

Persistent hot flashes despite adequate E2 levels (50–100 pg/mL): Check for SSRI/SNRI co-medication that blunts thermoregulation. Consider adding low-dose testosterone — emerging 2026 evidence supports testosterone as an adjunct for vasomotor symptoms refractory to estrogen alone.

Irregular breakthrough bleeding in the first 3 months: Common with sequential progestogen regimens. If it persists past 6 months, transvaginal ultrasound and endometrial biopsy are indicated. Not a reason to stop therapy prematurely.

Skin irritation from patch: Rotate application sites. Try gel or spray formulation. Hydrocortisone 1% applied to the skin site (not on the patch) reduces adhesive dermatitis in most patients.

Low libido persisting after E2 is optimized: Estrogen alone does not reliably restore libido. Testosterone (off-label in women; typically 1.5–2.5 mg/day transdermal) is the evidence-based addition. See testosterone replacement therapy for women.

Weight gain blamed on HRT: Body composition changes in menopause (visceral fat gain, muscle loss) are driven primarily by estrogen decline and aging — not by estrogen therapy. Adequately dosed estrogen may modestly attenuate visceral fat gain. If metabolic weight gain is a concern alongside hormone therapy, GoodLife Health's medical weight loss for women over 40 covers the combined approach.

Elevated triglycerides on lab recheck: Switch from oral to transdermal estradiol. Oral estrogen raises triglycerides; transdermal does not.

Tools and resources

• Menopause Rating Scale (MRS): Free, validated 11-item symptom questionnaire. Baseline + 8-week comparison is the most objective way to measure treatment response.
• Serum estradiol (E2) testing: Quest Diagnostics and LabCorp both run estradiol LC-MS/MS panels. GoodLife Health orders these directly for members.
• NAMS 2022 Hormone Therapy Position Statement: The authoritative US clinical reference. Publicly available at menopause.org.
• GoodLife Health [hormone optimization](https://goodlifehealth.ai/hormone-optimization) program: Clinician-reviewed labs, personalized protocol, ongoing titration — starting at $179/month as part of the direct primary care membership.

FAQ

What is the safest form of estrogen therapy for menopause in 2026? Transdermal estradiol (patch, gel, or spray) is the most clinically supported form. It avoids liver first-pass metabolism, does not raise clot risk the way oral estrogen does, and delivers consistent serum levels. Most evidence-based menopause clinicians in 2026 start here.

Do I need progesterone if I take estrogen for menopause? Yes — if your uterus is intact. Estrogen without progestogen stimulates endometrial growth and raises endometrial cancer risk. Women who have had a hysterectomy do not need progestogen.

How long does estrogen therapy for menopause take to work? Hot flash frequency typically drops 60–80% within 4–6 weeks at an effective dose. Genitourinary symptoms (dryness, pain) take longer — 8–12 weeks for meaningful improvement.

Is estrogen therapy for menopause safe after 60? Age alone is not a disqualifier. The key variables are years since menopause onset (the "timing hypothesis" favors starting within 10 years), cardiovascular risk factors, and whether the route is transdermal vs. oral. Women over 60 who are healthy, within 10 years of menopause, and using transdermal estradiol are not categorically excluded by any major 2026 guideline.

What's the difference between bioidentical and conventional hormone therapy? Bioidentical means the hormone molecule is structurally identical to what the human body produces — estradiol (E2) and micronized progesterone are both bioidentical and FDA-approved. Compounded bioidenticals from specialty pharmacies are a separate category with variable quality control. Most clinicians in 2026 prefer FDA-approved bioidentical formulations for consistent potency.

Can estrogen therapy help with weight gain during menopause? Estrogen decline drives visceral fat accumulation in menopause. Restoring estradiol to mid-follicular-phase levels (~50–100 pg/mL) does not guarantee weight loss, but it may slow the visceral fat gain associated with the estrogen drop. For women who need structured metabolic support alongside hormone therapy, both protocols can run concurrently.

How much does estrogen therapy cost without insurance? Generic transdermal estradiol patches run $20–$60/month at major pharmacies. Generic oral estradiol is under $15/month. Micronized progesterone (generic) is typically $30–$50/month. Lab monitoring (two panels in year one) adds $80–$200 depending on coverage. A direct primary care model that bundles labs, prescriptions, and clinician time is usually more cost-predictable than fee-for-service.

What happens if I stop estrogen therapy abruptly? Symptoms typically return — often sharply — within 2–6 weeks of stopping. Hot flashes can temporarily worsen before settling. Tapering the dose over 4–8 weeks reduces the rebound effect. Do not stop without a plan discussed with your clinician.

One last thing

The 2022 reanalysis of the WHI data (published in Menopause) found that women who started hormone therapy within 10 years of menopause onset had a 23% lower all-cause mortality compared to placebo at 18-year follow-up. That number does not make estrogen therapy mandatory — individual risk factors matter — but it reframes the conversation. The question is not "is estrogen safe enough to try," it is "what is the cost of not treating?"

Related guides

• Hormone optimization for women in perimenopause
• Bioidentical hormone replacement therapy for women
• How to know if you need hormone replacement therapy
• Testosterone replacement therapy for women — benefits and risks
• Medical weight loss for women over 40

References

1. Treatment of Symptoms of the Menopause: An Endocrine Society Clinical Practice Guideline. 2015. doi.org/10.1210/jc.2015-2236
2. Testosterone in Women — The Clinical Significance (Lancet Diabetes & Endocrinology). 2015. doi.org/10.1016/S2213-8587(15)00284-300284-3)